UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~September~~November 1710, 2025

Roivant Sciences Ltd.

(Exact name of registrant as specified in its charter)

Bermuda	001-40782	98-1173944
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

7th Floor

50 Broadway

London SW1H 0DB

United Kingdom

(Address of principal executive offices, and Zip Code)

+44 207 400-3347

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, $0.0000000341740141 per share		ROIV		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 72.0102. ~~Regulation~~Results FDof ~~Disclosure~~Operations and Financial Condition.

On ~~September~~November 1710, 2025, Roivant Sciences Ltd. (the “Company”) issued a press release announcing ~~positive~~its financial results ~~from~~for the ~~Phase~~fiscal 3quarter ~~VALOR~~ended ~~study~~September ~~evaluating~~30, ~~brepocitinib in dermatomyositis at its subsidiary Priovant Therapeutics~~2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K ~~and is incorporated herein by reference~~.

The information ~~furnished~~set forth under this “Item 72.~~01,~~02. Results of Operations and Financial Condition” (including ~~Exhibit~~the ~~99.1,~~exhibit thereto) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, ~~or subject~~as toamended, ~~the~~nor ~~liabilities~~shall ofit ~~that~~be ~~section~~incorporated orby ~~Sections~~reference 11in ~~and~~any ~~12(a)(2)~~filing ofmade by the ~~Securities~~Company ~~Act~~pursuant ofto ~~1933.~~the ~~The~~Securities ~~information~~Act inof ~~this Item 7.01~~1933, ~~including~~as ~~Exhibit 99.1~~amended, ~~shall~~other ~~not~~than beto ~~deemed~~the ~~incorporated~~extent bythat ~~reference~~such ~~into any other~~ filing ~~with the U.S.~~ ~~Securities~~ incorporates ~~Exchange Commission made~~ by ~~the~~reference ~~Company,~~any ~~whether made before~~ or ~~after~~all ~~the date hereof, regardless~~ of ~~any~~such ~~general~~information ~~incorporation~~by ~~language~~express inreference ~~such filing~~thereto.

Item 89.01. ~~Other~~Financial ~~Events~~Statements and Exhibits.

On September 17, 2025, the Company posted a presentation regarding the results from the Phase 3 VALOR study on the “Events & Presentations” page of its investor relations website at https://investor.roivant.com and will host a conference call and webcast to discuss the results at 8:00 a.m. E.D.T. on September 17, 2025. A copy of the presentation to be used by the Company during the conference call is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The contents of the Company’s website referenced in this Current Report on Form 8-K are not incorporated into this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description of Exhibit
99.1		Roivant Sciences Ltd. Press Release, dated ~~September~~November 1710, 2025.
99.2		Presentation, dated September 17, 2025.
104		Cover Page Interactive Data File (embedded with Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROIVANT SCIENCES LTD.
By:	/s/ Keyur Parekh
Name: Keyur Parekh
Title: Authorized Signatory
Dated: September 17, 2025
Dated: November 10, 2025

Filing Compare · Roivant Sciences Ltd.